{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T22:36:29Z","timestamp":1792708589291,"version":"4.5.0"},"reference-count":131,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T00:00:00Z","timestamp":1700524800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Generalized pustular psoriasis (GPP) is a rare, chronic, inflammatory skin disorder characterized by recurrent flares associated with skin erythema, desquamation, and widespread superficial sterile pustules, which may be severe (\u201clakes of pus\u201d). Systemic symptoms are often present, including malaise, fever, and skin pain. In GPP, innate immune responses are driven by abnormal activation of the interleukin (IL)-36-chemokine-neutrophil axis and excessive neutrophil infiltration. This review highlights the IL-36 pathway in the context of the IL-1 superfamily and describes how unopposed IL-36 signaling can lead to the development of GPP. Targeted inhibition of the IL-36 receptor (IL-36R) is an attractive therapeutic strategy in the treatment of GPP, including flare prevention and sustained disease control. Spesolimab is a first-in-class, humanized, monoclonal antibody that binds specifically to the IL-36R and antagonizes IL-36 signaling. Spesolimab was approved by the US Food and Drug Administration in September 2022 to treat GPP flares in adults and was subsequently approved for GPP flare treatment in other countries across the world. Anti-IL-36R therapy, such as spesolimab, can mitigate flares and address flare prevention in GPP, presumably through rebalancing IL-36 signaling and modulating the pro-inflammatory response of the downstream effectors.<\/jats:p>","DOI":"10.3389\/fimmu.2023.1292941","type":"journal-article","created":{"date-parts":[[2023,11,23]],"date-time":"2023-11-23T11:08:26Z","timestamp":1700737706000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":31,"title":["The role of the interleukin-36 axis in generalized pustular psoriasis: a review of the mechanism of action of spesolimab"],"prefix":"10.3389","volume":"14","author":[{"given":"Jason E.","family":"Hawkes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudha","family":"Visvanathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James G.","family":"Krueger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,11,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14386","article-title":"European consensus statement on phenotypes of pustular psoriasis","volume":"31","author":"Navarini","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2019.1708193","article-title":"The clinical, humanistic, and economic burden of generalized pustular psoriasis: a structured review","volume":"16","author":"Kharawala","year":"2020","journal-title":"Expert Rev Clin Immunol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-021-00654-z","article-title":"Clinical course and characteristics of generalized pustular psoriasis","volume":"23","author":"Choon","year":"2022","journal-title":"Am J Clin Dermatol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.21231","article-title":"Generalised pustular psoriasis: the case for rare disease and orphan designation","volume":"187","author":"Koren","year":"2022","journal-title":"Br J Dermatol"},{"key":"B5","article-title":"Generalized pustular psoriasis (Zumbusch): a French epidemiological survey","volume":"16","author":"Augey","year":"2006","journal-title":"Eur J Dermatol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"68","DOI":"10.2340\/00015555766871","article-title":"Generalized pustular psoriasis in Japan: two distinct groups formed by differences in symptoms and genetic background","volume":"76","author":"Ohkawara","year":"1996","journal-title":"Acta Derm Venereol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.5021\/ad.2017.29.6.761","article-title":"Prevalence of psoriasis in korea: A population-based epidemiological study using the korean national health insurance database","volume":"29","author":"Lee","year":"2017","journal-title":"Ann Dermatol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.18720","article-title":"Prevalence, comorbidities and mortality of generalized pustular psoriasis: A literature review","volume":"37","author":"Prinz","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.12070","article-title":"Clinical profile, morbidity, and outcome of adult-onset generalized pustular psoriasis: analysis of 102 cases seen in a tertiary hospital in Johor, Malaysia","volume":"53","author":"Choon","year":"2014","journal-title":"Int J Dermatol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2021.06.008","article-title":"Treatments and outcomes of generalized pustular psoriasis: A cohort of 1516 patients in a nationwide inpatient database in Japan","volume":"86","author":"Miyachi","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2009.09348.x","article-title":"Generalized pustular psoriasis induced by systemic glucocorticosteroids: four cases and recommendations for treatment","volume":"161","author":"Brenner","year":"2009","journal-title":"Br J Dermatol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-018-4034-0","article-title":"Paradoxical pustular psoriasis induced by ustekinumab in a patient with Crohn\u2019s disease-associated spondyloarthropathy","volume":"38","author":"Benzaquen","year":"2018","journal-title":"Rheumatol Int"},{"key":"B13","doi-asserted-by":"publisher","first-page":"87","DOI":"10.2147\/ptt.S126727","article-title":"Drug-induced psoriasis: clinical perspectives","volume":"7","author":"Balak","year":"2017","journal-title":"Psoriasis (Auckl)"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2016.08.056","article-title":"IL-1 and IL-36 are dominant cytokines in generalized pustular psoriasis","volume":"140","author":"Johnston","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2018.06.038","article-title":"Clinical and genetic differences between pustular psoriasis subtypes","volume":"143","author":"Twelves","year":"2019","journal-title":"J Allergy Clin Immunol Mar"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2022.2116003","article-title":"Generalized pustular psoriasis is a disease distinct from psoriasis vulgaris: evidence and expert opinion","volume":"18","author":"Bachelez","year":"2022","journal-title":"Expert Rev Clin Immunol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.2165\/11586900-000000000-00000","article-title":"Clinical and laboratory features in acute generalized pustular psoriasis: a retrospective study of 34 patients","volume":"12","author":"Borges-Costa","year":"2011","journal-title":"Am J Clin Dermatol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-020-0519-3","article-title":"\u201cAutoinflammatory psoriasis\u201d-genetics and biology of pustular psoriasis","volume":"18","author":"Uppala","year":"2021","journal-title":"Cell Mol Immunol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2017.07.004","article-title":"Psoriasis pathogenesis and the development of novel targeted immune therapies","volume":"140","author":"Hawkes","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"B20","first-page":"97","article-title":"Current developments in the immunology of psoriasis","volume":"93","author":"Gr\u00e4n","year":"2020","journal-title":"Yale J Biol Med"},{"key":"B21","unstructured":"FDA approves the first treatment option for generalized pustular psoriasis flares in adults2022"},{"key":"B22","unstructured":"SPEVIGO prescribing information2022"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2013.11.010","article-title":"The interleukin-1 family: back to the future","volume":"39","author":"Garlanda","year":"2013","journal-title":"Immunity"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22094344","article-title":"Exploring the role of IL-36 cytokines as a new target in psoriatic disease","volume":"22","author":"Iznardo","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2021.1886081","article-title":"The interleukin-1 family cytokines in psoriasis: pathogenetic role and therapeutic perspectives","volume":"17","author":"Iznardo","year":"2021","journal-title":"Expert Rev Clin Immunol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/imr.12621","article-title":"Overview of the IL-1 family in innate inflammation and acquired immunity","volume":"281","author":"Dinarello","year":"2018","journal-title":"Immunol Rev"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.808012","article-title":"The immunological impact of IL-1 family cytokines on the epidermal barrier","volume":"12","author":"Macleod","year":"2021","journal-title":"Front Immunol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24032795","article-title":"The role of the interleukin-1 family in complications of prematurity","volume":"24","author":"Green","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1111\/exd.14768","article-title":"Pathophysiology of generalized pustular psoriasis","volume":"32","author":"Young","year":"2023","journal-title":"Exp Dermatol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1007\/5584_2020_488","article-title":"Interleukin-36: structure, signaling and function","volume":"21","author":"Zhou","year":"2021","journal-title":"Adv Exp Med Biol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2020.108515","article-title":"The proinflammatory cytokine IL-36gamma is a global discriminator of harmless microbes and invasive pathogens within epithelial tissues","volume":"33","author":"Macleod","year":"2020","journal-title":"Cell Rep"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2015.12.072","article-title":"Neutrophil-derived proteases escalate inflammation through activation of IL-36 family cytokines","volume":"14","author":"Henry","year":"2016","journal-title":"Cell Rep"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1620954114","article-title":"Cathepsin S is the major activator of the psoriasis-associated proinflammatory cytokine IL-36gamma","volume":"114","author":"Ainscough","year":"2017","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0807865","article-title":"An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist","volume":"360","author":"Aksentijevich","year":"2009","journal-title":"N Engl J Med"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0809568","article-title":"An autoinflammatory disease due to homozygous deletion of the IL1RN locus","volume":"360","author":"Reddy","year":"2009","journal-title":"N Engl J Med"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1013068","article-title":"Interleukin-36-receptor antagonist deficiency and generalized pustular psoriasis","volume":"365","author":"Marrakchi","year":"2011","journal-title":"N Engl J Med"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajhg.2011.07.022","article-title":"Mutations in IL36RN\/IL1F5 are associated with the severe episodic inflammatory skin disease known as generalized pustular psoriasis","volume":"89","author":"Onoufriadis","year":"2011","journal-title":"Am J Hum Genet"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.652846","article-title":"IL-1 family antagonists in mouse and human skin inflammation","volume":"12","author":"Martin","year":"2021","journal-title":"Front Immunol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1111\/j.0022-202X.2004.22305.x","article-title":"Psoriasis-like cutaneous inflammation in mice lacking interleukin-1 receptor antagonist","volume":"122","author":"Shepherd","year":"2004","journal-title":"J Invest Dermatol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-018-0269-7","article-title":"Scoping review on use of drugs targeting interleukin 1 pathway in DIRA and DITRA","volume":"8","author":"Gomez-Garcia","year":"2018","journal-title":"Dermatol Ther (Heidelb)"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20070157","article-title":"Opposing activities of two novel members of the IL-1 ligand family regulate skin inflammation","volume":"204","author":"Blumberg","year":"2007","journal-title":"J Exp Med"},{"key":"B42","doi-asserted-by":"publisher","first-page":"118","DOI":"10.3892\/ijmm.2021.4951","article-title":"An update on genetic basis of generalized pustular psoriasis (Review)","volume":"47","author":"Zhou","year":"2021","journal-title":"Int J Mol Med"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2012.490","article-title":"Rare pathogenic variants in IL36RN underlie a spectrum of psoriasis-associated pustular phenotypes","volume":"133","author":"Setta-Kaffetzi","year":"2013","journal-title":"J Invest Dermatol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1016\/j.jaci.2014.09.043","article-title":"IL36RN mutations define a severe autoinflammatory phenotype of generalized pustular psoriasis","volume":"135","author":"Hussain","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2013.361","article-title":"IL36RN mutations in generalized pustular psoriasis: just the tip of the iceberg","volume":"133","author":"Capon","year":"2013","journal-title":"J Invest Dermatol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2013.230","article-title":"The majority of generalized pustular psoriasis without psoriasis vulgaris is caused by deficiency of interleukin-36 receptor antagonist","volume":"133","author":"Sugiura","year":"2013","journal-title":"J Invest Dermatol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000023068","article-title":"Association between mutation of interleukin 36 receptor antagonist and generalized pustular psoriasis: A PRISMA-compliant systematic review and meta-analysis","volume":"99","author":"Liu","year":"2020","journal-title":"Med (Baltimore)"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2013.285","article-title":"Loss of IL36RN function does not confer susceptibility to psoriasis vulgaris","volume":"134","author":"Berki","year":"2014","journal-title":"J Invest Dermatol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2015.288","article-title":"Activating CARD14 mutations are associated with generalized pustular psoriasis but rarely account for familial recurrence in psoriasis vulgaris","volume":"135","author":"Berki","year":"2015","journal-title":"J Invest Dermatol Dec"},{"key":"B50","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1016\/j.ajhg.2012.03.013","article-title":"Rare and common variants in CARD14, encoding an epidermal regulator of NF-kappaB, in psoriasis","volume":"90","author":"Jordan","year":"2012","journal-title":"Am J Hum Genet"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajhg.2014.04.005","article-title":"AP1S3 mutations are associated with pustular psoriasis and impaired Toll-like receptor 3 trafficking","volume":"94","author":"Setta-Kaffetzi","year":"2014","journal-title":"Am J Hum Genet"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2016.06.618","article-title":"AP1S3 mutations cause skin autoinflammation by disrupting keratinocyte autophagy and up-regulating IL-36 production","volume":"136","author":"Mahil","year":"2016","journal-title":"J Invest Dermatol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajhg.2020.06.020","article-title":"Loss-of-function myeloperoxidase mutations are associated with increased neutrophil counts and pustular skin disease","volume":"107","author":"Vergnano","year":"2020","journal-title":"Am J Hum Genet"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajhg.2020.07.001","article-title":"Myeloperoxidase modulates inflammation in generalized pustular psoriasis and additional rare pustular skin diseases","volume":"107","author":"Haskamp","year":"2020","journal-title":"Am J Hum Genet"},{"key":"B55","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1016\/j.jid.2019.11.024","article-title":"Rare loss-of-function mutation in SERPINA3 in generalized pustular psoriasis","volume":"140","author":"Frey","year":"2020","journal-title":"J Invest Dermatol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.16081","article-title":"SERPINA1, generalized pustular psoriasis, and adult-onset immunodeficiency","volume":"48","author":"Kantaputra","year":"2021","journal-title":"J Dermatol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdermsci.2021.11.009","article-title":"Pustular psoriasis as an autoinflammatory keratinization disease (AiKD): Genetic predisposing factors and promising therapeutic targets","volume":"105","author":"Akiyama","year":"2022","journal-title":"J Dermatol Sci"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-022-00881-0","article-title":"Generalized pustular psoriasis: A review on clinical characteristics, diagnosis, and treatment","volume":"13","author":"Rivera-Diaz","year":"2023","journal-title":"Dermatol Ther (Heidelb)"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15867","article-title":"The genetic basis for most patients with pustular skin disease remains elusive","volume":"178","author":"M\u00f6ssner","year":"2018","journal-title":"Br J Dermatol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2021.09.035","article-title":"Pustular psoriasis: Molecular pathways and effects of spesolimab in generalized pustular psoriasis","volume":"149","author":"Baum","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0802999","article-title":"Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the IL-23\/IL-17 axis","volume":"182","author":"van der Fits","year":"2009","journal-title":"J Immunol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.26508\/lsa.202000688","article-title":"IL-36 signaling in keratinocytes controls early IL-23 production in psoriasis-like dermatitis","volume":"3","author":"Goldstein","year":"2020","journal-title":"Life Sci Alliance"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1172\/JCI63451","article-title":"Psoriasiform dermatitis is driven by IL-36-mediated DC-keratinocyte crosstalk","volume":"122","author":"Tortola","year":"2012","journal-title":"J Clin Invest"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.26508\/lsa.201900586","article-title":"Keratinocyte interleukin-36 receptor expression orchestrates psoriasiform inflammation in mice","volume":"3","author":"Hernandez-Santana","year":"2020","journal-title":"Life Sci Alliance"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1801519","article-title":"Efficacy of chemokine receptor inhibition in treating IL-36alpha-induced psoriasiform inflammation","volume":"202","author":"Campbell","year":"2019","journal-title":"J Immunol"},{"key":"B66","doi-asserted-by":"publisher","first-page":"2992","DOI":"10.1038\/jid.2015.289","article-title":"Unprocessed interleukin-36alpha regulates psoriasis-like skin inflammation in cooperation with interleukin-1","volume":"135","author":"Milora","year":"2015","journal-title":"J Invest Dermatol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00746","article-title":"Neutrophil extracellular traps promote inflammatory responses in psoriasis via activating epidermal TLR4\/IL-36R crosstalk","volume":"10","author":"Shao","year":"2019","journal-title":"Front Immunol"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2017.10.013","article-title":"Research techniques made simple: murine models of human psoriasis","volume":"138","author":"Hawkes","year":"2018","journal-title":"J Invest Dermatol"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1152\/ajplung.2001.280.6.L1094","article-title":"IL-8 activates endothelial cell CXCR1 and CXCR2 through Rho and Rac signaling pathways","volume":"280","author":"Schraufstatter","year":"2001","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.172.5.2731","article-title":"Of mice and not men: differences between mouse and human immunology","volume":"172","author":"Mestas","year":"2004","journal-title":"J Immunol"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20133318","article-title":"The significance of IL-36 hyperactivation and IL-36R targeting in psoriasis","volume":"20","author":"Madonna","year":"2019","journal-title":"Int J Mol Sci"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M111.267922","article-title":"Interleukin-36 (IL-36) ligands require processing for full agonist (IL-36\u03b1, IL-36\u03b2, and IL-36\u03b3) or antagonist (IL-36Ra) activity","volume":"286","author":"Towne","year":"2011","journal-title":"J Biol Chem"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2014.532","article-title":"IL-36gamma (IL-1F9) is a biomarker for psoriasis skin lesions","volume":"135","author":"D\u2019Erme","year":"2015","journal-title":"J Invest Dermatol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2021.01.019","article-title":"IL-36 and IL-17A cooperatively induce a psoriasis-like gene expression response in human keratinocytes","volume":"141","author":"Miura","year":"2021","journal-title":"J Invest Dermatol"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2011.234","article-title":"Inter-regulation of Th17 cytokines and the IL-36 cytokines in vitro and in vivo: implications in psoriasis pathogenesis","volume":"131","author":"Carrier","year":"2011","journal-title":"J Invest Dermatol"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.14318","article-title":"Successful treatment with interleukin-17A antagonists of generalized pustular psoriasis in patients without IL36RN mutations","volume":"45","author":"Wilsmann-Theis","year":"2018","journal-title":"J Dermatol"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1358\/dot.2019.55.9.3020159","article-title":"The role of IL-17 and IL-17 receptor inhibitors in the management of generalized pustular psoriasis","volume":"55","author":"Plachouri","year":"2019","journal-title":"Drugs Today (Barc)"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.13306","article-title":"Efficacy and safety of secukinumab in patients with generalized pustular psoriasis: A 52-week analysis from phase III open-label multicenter Japanese study","volume":"43","author":"Imafuku","year":"2016","journal-title":"J Dermatol"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.13622","article-title":"Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: Results from a 52-week, open-label, phase 3 study (UNCOVER-J)","volume":"44","author":"Saeki","year":"2017","journal-title":"J Dermatol"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14702","article-title":"Efficacy and safety of brodalumab in patients with generalized pustular psoriasis and psoriatic erythroderma: results from a 52-week, open-label study","volume":"176","author":"Yamasaki","year":"2017","journal-title":"Br J Dermatol Mar"},{"key":"B81","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1016\/j.jid.2019.08.444","article-title":"IL-36 promotes systemic IFN-I responses in severe forms of psoriasis","volume":"140","author":"Catapano","year":"2020","journal-title":"J Invest Dermatol Apr"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2017.1353853","article-title":"Generation and functional characterization of anti-human and anti-mouse IL-36R antagonist monoclonal antibodies","volume":"9","author":"Ganesan","year":"2017","journal-title":"MAbs"},{"key":"B83","unstructured":"European Commission approves SPEVIGO2022"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1811317","article-title":"Inhibition of the interleukin-36 pathway for the treatment of generalized pustular psoriasis","volume":"380","author":"Bachelez","year":"2019","journal-title":"N Engl J Med"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2111563","article-title":"Trial of spesolimab for generalized pustular psoriasis","volume":"385","author":"Bachelez","year":"2021","journal-title":"N Engl J Med"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-022-00830-x","article-title":"Commentary on a clinical trial of spesolimab, a humanized anti-interleukin-36 receptor monoclonal antibody, in generalized pustular psoriasis","volume":"12","author":"Shao","year":"2022","journal-title":"Dermatol Ther (Heidelb)"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-022-01801-4","article-title":"Spesolimab: first approval","volume":"82","author":"Blair","year":"2022","journal-title":"Drugs"},{"key":"B88","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s40257-021-00653-0","article-title":"Clinical disease measures in generalized pustular psoriasis","volume":"23","author":"Burden","year":"2022","journal-title":"Am J Clin Dermatol"},{"key":"B89","first-page":"34988979","article-title":"Spesolimab alters the molecular profile of lesional skin in patients with generalized pustular psoriasis with a clinical response (Abstract FC04)","volume":"186","author":"Farag","year":"2021","journal-title":"Br J Dermatol (Psoriasis: From Gene to Clinic 9th Int Congress; London UK; 9 to 11 December 2021)"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.18820","article-title":"Spesolimab improves patient-reported outcomes in patients with generalized pustular psoriasis: Results from the Effisayil 1 study","volume":"37","author":"Navarini","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.16609","article-title":"Efficacy and safety of spesolimab in Asian patients with a generalized pustular psoriasis flare: Results from the randomized, double-blind, placebo-controlled Effisayil 1 study","volume":"50","author":"Morita","year":"2023","journal-title":"J Dermatol"},{"key":"B92","doi-asserted-by":"crossref","first-page":"AB54","DOI":"10.1016\/j.jaad.2022.06.248","article-title":"(Abstract 33007) Efficacy of spesolimab for the treatment of GPP flares across prespecified patient subgroups in the Effisayil 1 study","volume":"87","author":"Burden","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-022-00835-6","article-title":"Design of effisayil 2: A randomized, double-blind, placebo-controlled study of spesolimab in preventing flares in patients with generalized pustular psoriasis","volume":"13","author":"Morita","year":"2023","journal-title":"Dermatol Ther (Heidelb) Jan"},{"key":"B94","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1016\/S0140-6736(23)01378-8","article-title":"Efficacy and safety of subcutaneous spesolimab for the prevention of generalised pustular psoriasis flares (Effisayil 2): an international, multicentre, randomised, placebo-controlled trial","volume":"402","author":"Morita","year":"2023","journal-title":"Lancet"},{"key":"B95","unstructured":"Effisayil\u2122 ON: A study to test long-term treatment with spesolimab in people with generalized pustular psoriasis who took part in a previous study"},{"key":"B96","first-page":"AB44","article-title":"Effisayil ON, an open-label, long-term extension study of spesolimab treatment in patients with generalized pustular psoriasis: interim results for flare treatment","volume-title":"J American Academy of Dermatology","author":"Navarini","year":"2023"},{"key":"B97","article-title":"Spesolimab alters the molecular profile of lesional skin in patients with generalized pustular psoriasis with a clinical response (Abstract 103)","volume-title":"4th Inflammatory Skin Disease Summit (ISDS), New York, November 3-6, 2021","author":"Farag","year":""},{"key":"B98","unstructured":"(Trial protocol) A Single Arm Multiple Dose Study to Assess the Efficacy and Safety of ANB019 in Subjects with Generalized Pustular Psoriasis"},{"key":"B99","unstructured":"AnaptysBio presents updated data from imsidolimab phase 2 GALLOP trial in generalized pustular psoriasis"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljad083","article-title":"Imsidolimab, an anti-interleukin-36 receptor monoclonal antibody, for the treatment of generalized pustular psoriasis: results from the phase II GALLOP trial","volume":"189","author":"Warren","year":"2023","journal-title":"Br J Dermatol"},{"key":"B101","doi-asserted-by":"publisher","first-page":"AB70","DOI":"10.1016\/j.jaad.2022.06.313","article-title":"Imsidolimab in the treatment of adult subjects with generalized pustular psoriasis: Design of a pivotal phase 3 clinical trial and a long-term extension study","volume":"87","author":"Gudjonsson","year":"2022","journal-title":"J American Academy of Dermatology"},{"key":"B102","doi-asserted-by":"publisher","first-page":"9089","DOI":"10.1038\/s41598-019-45626-w","article-title":"Small molecule IL-36gamma antagonist as a novel therapeutic approach for plaque psoriasis","volume":"9","author":"Todorovic","year":"2019","journal-title":"Sci Rep"},{"key":"B103","unstructured":"Ascending dose study of the safety and tolerability of REGN6490 in healthy volunteers (NCT04616079)"},{"key":"B104","unstructured":"Study of the safety, tolerability, and pharmacokinetics of REGN6490 in healthy Japanese adult volunteers (NCT04616105)"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-021-00652-1","article-title":"Diagnosis of generalized pustular psoriasis","volume":"23","author":"Fujita","year":"2022","journal-title":"Am J Clin Dermatol"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.5021\/ad.2016.28.4.451","article-title":"Immunohistochemical comparison of IL-36 and the IL-23\/th17 axis of generalized pustular psoriasis and acute generalized exanthematous pustulosis","volume":"28","author":"Song","year":"2016","journal-title":"Ann Dermatol"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2018.10.023","article-title":"Culprit drugs induce specific IL-36 overexpression in acute generalized exanthematous pustulosis","volume":"139","author":"Meier-Schiesser","year":"2019","journal-title":"J Invest Dermatol"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1159\/000529218","article-title":"Acute generalized exanthematous pustulosis: clinical characteristics, pathogenesis, and management","volume":"239","author":"Stadler","year":"2023","journal-title":"Dermatol"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-020-00503-5","article-title":"Palmoplantar pustulosis: recent advances in etiopathogenesis and emerging treatments","volume":"21","author":"Misiak-Galazka","year":"2020","journal-title":"Am J Clin Dermatol"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-023-01002-1","article-title":"Spesolimab efficacy and safety in patients with moderate-to-severe palmoplantar pustulosis: A multicentre, double-blind, randomised, placebo-controlled, phase IIb, dose-finding study","volume":"13","author":"Burden","year":"2023","journal-title":"Dermatol Ther (Heidelb)"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-021-00493-0","article-title":"Unmet medical needs in the treatment and management of generalized pustular psoriasis flares: evidence from a survey of corrona registry dermatologists","volume":"11","author":"Strober","year":"2021","journal-title":"Dermatol Ther (Heidelb)"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1080\/1744666x.2019.1648209","article-title":"An update on generalized pustular psoriasis","volume":"15","author":"Gooderham","year":"2019","journal-title":"Expert Rev Clin Immunol"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-021-00661-2","article-title":"Unmet educational needs and clinical practice gaps in the management of generalized pustular psoriasis: global perspectives from the front line","volume":"12","author":"Strober","year":"2022","journal-title":"Dermatol Ther (Heidelb)"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.18851","article-title":"Generalized pustular psoriasis: a global Delphi consensus on clinical course, diagnosis, treatment goals, and disease management","volume":"37","author":"Puig","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1172\/JCI144336","article-title":"IL-36 in chronic inflammation and fibrosis - bridging the gap","volume":"131","author":"Elias","year":"2021","journal-title":"J Clin Invest"},{"key":"B116","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1089\/jir.2021.0173","article-title":"Interleukin-1 receptor-like 2: one receptor, three agonists, and many implications","volume":"42","author":"Manzanares-Meza","year":"2022","journal-title":"J Interferon Cytokine Res"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1038\/mi.2015.134","article-title":"IL-36alpha expression is elevated in ulcerative colitis and promotes colonic inflammation","volume":"9","author":"Russell","year":"2016","journal-title":"Mucosal Immunol"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izaa232","article-title":"The diverse roles of the IL-36 family in gastrointestinal inflammation and resolution","volume":"27","author":"Leon","year":"2021","journal-title":"Inflammation Bowel Dis"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.139930","article-title":"Contribution of plasma cells and B cells to hidradenitis suppurativa pathogenesis","volume":"5","author":"Gudjonsson","year":"2020","journal-title":"JCI Insight"},{"key":"B120","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/exd.14338","article-title":"Target molecules for future hidradenitis suppurativa treatment","author":"Zouboulis","year":"2021","journal-title":"Exp Dermatol"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kez358","article-title":"Interleukin-36 family dysregulation drives joint inflammation and therapy response in psoriatic arthritis","volume":"59","author":"Boutet","year":"2020","journal-title":"Rheumatol (Oxford)"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-202264","article-title":"The novel cytokine interleukin-36alpha is expressed in psoriatic and rheumatoid arthritis synovium","volume":"72","author":"Frey","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aan2585","article-title":"TGF-beta type 2 receptor-mediated modulation of the IL-36 family can be therapeutically targeted in osteoarthritis","volume":"11","author":"Li","year":"2019","journal-title":"Sci Transl Med"},{"key":"B124","doi-asserted-by":"publisher","first-page":"76","DOI":"10.3892\/br.2021.1452","article-title":"Elevated levels of serum IL-36alpha in patients with systemic lupus erythematosus","volume":"15","author":"Wang","year":"2021","journal-title":"BioMed Rep"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2018.03.011","article-title":"Increased serum IL-36alpha and IL-36gamma levels in patients with systemic lupus erythematosus: Association with disease activity and arthritis","volume":"58","author":"Mai","year":"2018","journal-title":"Int Immunopharmacol"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-022-00699-8","article-title":"Pyoderma gangrenosum: an updated literature review on established and emerging pharmacological treatments","volume":"23","author":"Maronese","year":"2022","journal-title":"Am J Clin Dermatol"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2021.08.024","article-title":"Netherton syndrome subtypes share IL-17\/IL-36 signature with distinct IFN-\u03b1 and allergic responses","volume":"149","author":"Barbieux","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"B128","first-page":"AB89","article-title":"Spesolimab for hidradenitis suppurativa: A proof-of-concept study","volume-title":"Journal of the American Academy of Dermatology","author":"Alavi","year":"2023"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1016\/j.cytogfr.2020.06.006","article-title":"IL-36 in chronic inflammation and cancer","volume":"55","author":"Neurath","year":"2020","journal-title":"Cytokine Growth Factor Rev"},{"key":"B130","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/978-3-030-38315-2_8","article-title":"IL-36 signaling in the tumor microenvironment","volume":"1240","author":"Chelvanambi","year":"2020","journal-title":"Adv Exp Med Biol"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-021-03909-4","article-title":"IL-36 cytokines in inflammatory and Malignant diseases: not the new kid on the block anymore","volume":"78","author":"Byrne","year":"2021","journal-title":"Cell Mol Life Sci"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1292941\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,23]],"date-time":"2023-11-23T11:08:36Z","timestamp":1700737716000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1292941\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,21]]},"references-count":131,"alternative-id":["10.3389\/fimmu.2023.1292941"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1292941","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,21]]},"article-number":"1292941"}}